These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 30553476)

  • 1. An expression quantitative trait locus variant for LKB1 gene predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer.
    Seo H; Jung DK; Kang HG; Jeong JY; Lee SY; Choi JE; Hong MJ; Do SK; Lee JH; Lee WK; Shin KM; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
    Cancer Genet; 2018 Dec; 228-229():73-82. PubMed ID: 30553476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
    Lee SY; Kang HG; Yoo SS; Kang YR; Choi YY; Lee WK; Choi JE; Jeon HS; Shin KM; Oh IJ; Kim KS; Lee J; Cha SI; Kim CH; Kim YC; Park JY
    Lung Cancer; 2013 Nov; 82(2):330-9. PubMed ID: 23973201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.
    Lee SY; Jung DK; Choi JE; Jin CC; Hong MJ; Do SK; Kang HG; Lee WK; Seok Y; Lee EB; Jeong JY; Shin KM; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
    Sci Rep; 2016 May; 6():25952. PubMed ID: 27181838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.
    Hong MJ; Lee SY; Choi JE; Jin CC; Kang HJ; Baek SA; Lee SY; Shin KM; Jeong JY; Lee WK; Yoo SS; Lee J; Cha SI; Kim CH; Son JW; Park JY
    Oncotarget; 2016 Mar; 7(13):15948-58. PubMed ID: 26893365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory variants in cancer-related pathway genes predict survival of patients with surgically resected non-small cell lung cancer.
    Shin KM; Hong MJ; Lee SY; Jin CC; Baek SA; Lee JH; Choi JE; Kang HG; Lee WK; Seok Y; Lee EB; Jeong JY; Yoo SS; Lee J; Cha SI; Kim CH; Kim YC; Oh IJ; Na KJ; Cho S; Jheon S; Park JY
    Gene; 2018 Mar; 646():56-63. PubMed ID: 29289609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms in Glycolysis-Related Genes Are Associated with Clinical Outcomes of Paclitaxel-Cisplatin Chemotherapy in Non-Small Cell Lung Cancer.
    Choi SH; Jin CC; Do SK; Lee SY; Choi JE; Kang HG; Kim JH; Lee JH; Hong MJ; Lee WK; Jeong JY; Shin KM; Lee YH; Seo H; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
    Oncology; 2020; 98(7):468-477. PubMed ID: 32252059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variations within 3'-UTR of MDM4 gene contribute to clinical outcomes of advanced non-small cell lung cancer patients following platinum-based chemotherapy.
    Yang Y; Gao W; Ding X; Xu W; Liu D; Su B; Sun Y
    Oncotarget; 2017 Mar; 8(10):16313-16324. PubMed ID: 27462918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-binding site SNPs in deregulated genes are associated with clinical outcome of non-small cell lung cancer.
    Xu J; Tian S; Yin Z; Wu S; Liu L; Qian Y; Pei D; Gao W; Xu J; Yin Y; Liu P; Shu Y
    Lung Cancer; 2014 Sep; 85(3):442-8. PubMed ID: 24997136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of polymorphisms in translesion synthesis genes with prognosis of advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
    Zhang X; Chen Q; Chen J; He C; Mao J; Dai Y; Yang X; Hu W; Zhu C; Chen B
    J Surg Oncol; 2016 Jan; 113(1):17-23. PubMed ID: 26611653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment.
    Qian J; Gu S; Wu Q; Zhao X; Wu W; Gao Z; Zhang W; Tan X; Wang H; Wang J; Fan W; Chen H; Han B; Lu D; Wei Q; Jin L
    Chest; 2012 Sep; 142(3):680-689. PubMed ID: 22441531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer.
    Provencio M; Camps C; Cobo M; De las Peñas R; Massuti B; Blanco R; Alberola V; Jimenez U; Delgado JR; Cardenal F; Tarón M; Ramírez JL; Sanchez A; Rosell R
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):883-90. PubMed ID: 23053267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy.
    Park HS; Lim SM; Shin HJ; Cho A; Shin JG; Lee MG; Kim HR; Kim JH; Cho BC
    Pharmacogenet Genomics; 2016 Mar; 26(3):116-25. PubMed ID: 26641474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An ERCC4 regulatory variant predicts grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy.
    Zhang R; Jia M; Xu Y; Qian D; Wang M; Zhu M; Sun M; Chang J; Wei Q
    Int J Cancer; 2018 Mar; 142(6):1218-1229. PubMed ID: 29134637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.
    Pallaud C; Reck M; Juhasz E; Szima B; Yu CJ; Burdaeva O; Orlov S; Hilton M; Archer V; Mok T
    Lung Cancer; 2014 Oct; 86(1):67-72. PubMed ID: 25154982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer.
    Shiraishi K; Kohno T; Tanai C; Goto Y; Kuchiba A; Yamamoto S; Tsuta K; Nokihara H; Yamamoto N; Sekine I; Ohe Y; Tamura T; Yokota J; Kunitoh H
    J Clin Oncol; 2010 Nov; 28(33):4945-52. PubMed ID: 20940192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival prediction of tuberous sclerosis complex gene variant in patients with advanced non-small-cell lung cancer treated with platinum doublet.
    Ryu JS; Lim JH; Kim HJ; Kim MJ; Park MH; Kim JS
    Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30842342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Variants of the MDM2 Gene Are Predictive of Treatment-Related Toxicities and Overall Survival in Patients With Advanced NSCLC.
    Qian J; Liu H; Gu S; Wu Q; Zhao X; Wu W; Wang H; Wang J; Chen H; Zhang W; Wei Q; Jin L; Lu D
    Clin Lung Cancer; 2015 Sep; 16(5):e37-53. PubMed ID: 25818095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional intronic ERCC1 polymorphism from regulomeDB can predict survival in lung cancer after surgery.
    Lee SY; Hong MJ; Jeon HS; Choi YY; Choi JE; Kang HG; Jung DK; Jin C; Do SK; Yoo SS; Seok Y; Lee EB; Shin KM; Jeong JY; Lee WK; Lee J; Cha SI; Kim CH; Kim YT; Jheon S; Park JY
    Oncotarget; 2015 Sep; 6(27):24522-32. PubMed ID: 26056042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia pathway genetic variants predict survival of non-small-cell lung cancer patients receiving platinum-based chemotherapy.
    Li R; Gu J; Heymach JV; Shu X; Zhao L; Han B; Ye Y; Roth J; Wu X
    Carcinogenesis; 2017 Apr; 38(4):419-424. PubMed ID: 28186269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.